Jianjun Jay Zhang is Professor of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. He serves as the Chair of Lung Moon Shot GEMINI Program, the Director of Lung Cancer Interception Program and Director of Lung Cancer Genomics Program. He is a physician scientist dedicated to clinical and translational lung cancer research with specific expertise in lung cancer genomics and immunogenomics. His research has been focusing on elucidating the mechanisms and clinical implications of tumor heterogeneity; the impact of cancer molecular features on host anti-tumor immune surveillance during cancer evolution with or without therapy and the molecular mechanisms underlying the transformation of premalignancy into invasive lung cancer via integrative wet laboratory, bioinformatics and computational biology approaches. His group has published a series of studies on the genomic, transcriptomic, methylation, and T cell receptor intratumor heterogeneity of lung cancers and demonstrated that complex molecular heterogeneity is associated with impaired T cell response and increased risks of postsurgical recurrence of lung cancers. His group has also made critical contributions to understand the molecular evolution during early lung carcinogenesis.  His group has demonstrated progressive genomic/epigenomic alterations from normal lung cells to lung premalignancies, preinvasive lung cancers and invasive lung cancers accompanied by a gradually less effective and more intensively regulated immune response; driver mutations, chromosomal copy number aberrations and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in precancer into dominant clones in invasive lung cancer. He has published >250 peer-reviewed papers in high-impact journals including Nature, Science, Cell, Lancet Oncology, Journal of Clinical Oncology, etc. His studies have led to the development of two unique clinical trials in a completely novel clinical research field: targeting tumor immune microenvironment for lung cancer prevention: IMPRINT-Lung and Can-Prevent-Lung. The planned interim analysis of Can-Prevent-Lung trial has demonstrated early evidence of success of immune interception for lung cancer prevention.